Company news
Everest Medicines Ltd. news in 2026
Everest Medicines Ltd.'s news releases, calls and decks from 2026, newest first.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 4, 2026
Notification Letter to Registered Shareholders - Virtual Meeting Arrangements for the Extraordinary General Meeting
October 30, 2026
The Strategic Cooperation Framework Agreement
October 30, 2026
Form of proxy for the extraordinary general meeting to be held on Monday, 16 November 2026
October 30, 2026
Notice of extraordinary general meeting
October 30, 2026
(1) Continuing connected transactions in relation to the strategic cooperation framework agreement; and (2) notice of extraordinary general meeting
October 30, 2026
Book closure period for extraordinary general meeting
October 28, 2026
Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
October 8, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
Terms of reference of the environmental, social and governance committee
September 28, 2026
List of directors and their roles and functions
September 28, 2026
Establishment of environmental, social and governance committee
September 28, 2026
Next Day Disclosure Return
September 28, 2026
Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults
September 3, 2026
Everest Medicines Announces Interim Results for First Half of 2026
August 18, 2026
Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026
August 5, 2026
Everest Medicines Announces Participation in Upcoming Investor Conferences
July 27, 2026
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
July 7, 2026
Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia
June 25, 2026
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules
June 24, 2026
Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel
June 8, 2026
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China
June 7, 2026
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market
June 4, 2026
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
June 2, 2026
Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited
April 7, 2026
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China
March 22, 2026
Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited
March 17, 2026
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call
March 16, 2026
Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
March 13, 2026
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026
March 10, 2026
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China
March 9, 2026
Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis
February 6, 2026
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
February 4, 2026
Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Decks in 2026
- H1 2026 Earnings Presentation
Earnings · 30 slides · August 2026